JC

JCR Pharmaceuticals Co.,Ltd.

Develops therapies for rare genetic diseases, CNS disorders, and regenerative medicine.

4552 | T

Overview

Corporate Details

ISIN(s):
JP3701000006
LEI:
Country:
Japan
Address:
芦屋市春日町3番19号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company focused on the research, development, and manufacturing of treatments for rare and genetic diseases. The company is engaged in biopharmaceutical innovation, particularly in areas like regenerative medicine and therapies for Central Nervous System (CNS) disorders. Its portfolio includes medical drugs, regenerative products, and pharmaceutical raw materials, with a key mission to create breakthrough therapies that address some of the world's most complex healthcare challenges for patients and medical professionals.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 03:10
Registration Form
確認書
Japanese 8.3 KB
2025-11-14 03:08
Interim Report
半期報告書-第51期(2025/04/01-2026/03/31)
Japanese 209.0 KB
2025-06-27 02:00
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2025-06-25 08:38
Registration Form
確認書
Japanese 8.3 KB
2025-06-25 08:37
Governance Information
内部統制報告書-第50期(2024/04/01-2025/03/31)
Japanese 25.8 KB
2025-06-25 08:36
Annual Report
有価証券報告書-第50期(2024/04/01-2025/03/31)
Japanese 1.7 MB
2024-11-14 03:16
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-11-14 03:15
Interim Report
半期報告書-第50期(2024/04/01-2025/03/31)
Japanese 219.6 KB
2024-07-23 09:30
Share Issue/Capital Change
臨時報告書
Japanese 28.5 KB
2024-06-28 02:00
Post-Annual General Meeting Information
臨時報告書
Japanese 26.0 KB
2024-06-26 07:12
Regulatory News Service
確認書
Japanese 8.3 KB
2024-06-26 07:11
Regulatory News Service
内部統制報告書-第49期(2023/04/01-2024/03/31)
Japanese 23.5 KB
2024-06-26 07:07
Annual Report
有価証券報告書-第49期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-02-14 03:07
Report Publication Announcement
確認書
Japanese 8.2 KB
2024-02-14 03:06
Quarterly Report
四半期報告書-第49期第3四半期(2023/10/01-2023/12/31)
Japanese 169.6 KB

Automate Your Workflow. Get a real-time feed of all JCR Pharmaceuticals Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for JCR Pharmaceuticals Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for JCR Pharmaceuticals Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark
GMAB
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea
225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea
314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea
228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland
GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea
066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America
GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway
GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America
GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS

Talk to a Data Expert

Have a question? We'll get back to you promptly.